SCHEMBL24253843

SCHEMBL24253843

O=C1CCCC2(CCN(c3ncc4ccc(C(F)(F)F)cc4n3)CC2)N1c1ccc(Cl)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.34
GPR119 Q8TDV5 2/20 0.34
SCD O00767 6/20 0.33
HCRTR1 O43613 1/20 0.32
HCRTR2 O43614 1/20 0.32
KCNH2 Q12809 1/20 0.32
LTC4S Q16873 1/20 0.32
ADRA1B P35368 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
ATM Q13315 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424819 1.00 AOC3 (0.34) AOC3GPR119SCDHCRTR1HCRTR2
SCHEMBL24253712 0.82 KMT2A (0.41) AOC3HCRTR1HCRTR2KMT2AALDH1A1
SCHEMBL30423539 0.82 KMT2A (0.41) AOC3HCRTR1HCRTR2KMT2AALDH1A1
SCHEMBL30423561 0.80 DPP4 (0.36) AOC3HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL24253726 0.80 DPP4 (0.36) AOC3HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL24253713 0.80 HCRTR1 (0.42) GPR119HCRTR1HCRTR2KCNH2ADRA1B
SCHEMBL30423555 0.80 HCRTR1 (0.42) GPR119HCRTR1HCRTR2KCNH2ADRA1B
SCHEMBL24253827 0.75 AOC3 (0.33) AOC3HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL30424094 0.75 AOC3 (0.33) AOC3HCRTR1HCRTR2KCNH2LTC4S
SCHEMBL24253822 0.74 SCD (0.35) SCDHCRTR1HCRTR2KCNH2LTC4S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 AOC3 3531/4885GPR119 418/4885SCD 3776/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 AOC3 3531/4885GPR119 418/4885SCD 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.